Dapoflit MV Tablet is a clinically effective triple-drug oral formulation combining Dapagliflozin 10mg, Metformin 1000mg, and Vildagliptin 100mg, designed for comprehensive glycemic management in patients with type-2 diabetes mellitus who require intensified therapy.
Dapagliflozin facilitates glucose excretion via the kidneys, Metformin reduces hepatic glucose production and improves insulin sensitivity, while Vildagliptin enhances incretin-mediated insulin secretion. Together, these mechanisms provide optimal control of fasting and postprandial blood glucose levels.
This combination is ideal for patients inadequately controlled on dual therapy, offering improved glycemic stability with a favorable safety profile. It is commonly prescribed by diabetologists and physicians for long-term management of chronic diabetes.
Adding Dapoflit MV Tablet to your diabetes and metabolic-care portfolio strengthens your market offerings, creating opportunities in retail pharmacy supply, hospital procurement, institutional distribution, export markets, and third-party manufacturing. Its high prescription demand ensures consistent commercial performance.
Some patients may experience nausea, diarrhea, abdominal discomfort, headache, dizziness, or increased urination. Rarely, hypoglycemia (especially when used with other antidiabetic agents), urinary tract infections, genital infections, or lactic acidosis may occur.
Dapoflit MV Tablet is indicated for the management of type 2 diabetes mellitus in patients who require combination therapy to achieve better glycemic control when diet and exercise alone are insufficient.
Use strictly under medical supervision. Regular monitoring of blood glucose, kidney function, and signs of hypoglycemia is recommended. Avoid use in patients with severe renal impairment, metabolic acidosis, or diabetic ketoacidosis. Follow the prescribed dosage and lifestyle recommendations carefully.
Store in a cool, dry place below 25°C, away from light and moisture. Keep out of reach of children.